1. Home
  2. KPLT vs NXTC Comparison

KPLT vs NXTC Comparison

Compare KPLT & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Katapult Holdings Inc.

KPLT

Katapult Holdings Inc.

HOLD

Current Price

$6.94

Market Cap

32.7M

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$9.90

Market Cap

35.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KPLT
NXTC
Founded
2012
2015
Country
United States
United States
Employees
94
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.7M
35.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
KPLT
NXTC
Price
$6.94
$9.90
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$10.00
$23.00
AVG Volume (30 Days)
22.4K
28.5K
Earning Date
03-11-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,378,000.00
Revenue This Year
$18.62
N/A
Revenue Next Year
$15.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.50
$0.23
52 Week High
$24.15
$15.74

Technical Indicators

Market Signals
Indicator
KPLT
NXTC
Relative Strength Index (RSI) 56.04 34.46
Support Level $5.78 $8.32
Resistance Level $7.58 $14.01
Average True Range (ATR) 0.40 1.16
MACD 0.03 -0.24
Stochastic Oscillator 73.48 16.58

Price Performance

Historical Comparison
KPLT
NXTC

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: